Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Mus musculus | RAR-related orphan receptor gamma | Starlite/ChEMBL | No references |
Homo sapiens | APEX nuclease (multifunctional DNA repair enzyme) 1 | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | ap endonuclease | 0.0023 | 0.0021 | 1 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease, putative | 0.0023 | 0.0021 | 0.5 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease | 0.0023 | 0.0021 | 0.5 |
Mycobacterium tuberculosis | Probable 1-deoxy-D-xylulose 5-phosphate reductoisomerase Dxr (DXP reductoisomerase) (1-deoxyxylulose-5-phosphate reductoisomeras | 0.3593 | 0.7214 | 1 |
Schistosoma mansoni | ap endonuclease | 0.0023 | 0.0021 | 1 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.0023 | 0.0021 | 0.5 |
Loa Loa (eye worm) | exodeoxyribonuclease III family protein | 0.0023 | 0.0021 | 1 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0023 | 0.0021 | 0.5 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.0023 | 0.0021 | 0.5 |
Entamoeba histolytica | exodeoxyribonuclease III, putative | 0.0023 | 0.0021 | 0.5 |
Echinococcus granulosus | DNA apurinic or apyrimidinic site lyase | 0.0023 | 0.0021 | 1 |
Echinococcus multilocularis | DNA (apurinic or apyrimidinic site) lyase | 0.0023 | 0.0021 | 1 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0023 | 0.0021 | 0.5 |
Leishmania major | apurinic/apyrimidinic endonuclease-redox protein | 0.0023 | 0.0021 | 0.5 |
Brugia malayi | exodeoxyribonuclease III family protein | 0.0023 | 0.0021 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 59.85 uM | PUBCHEM_BIOASSAY: Dose Response confirmation of uHTS small molecule inhibitors of tim10-1 yeast via a luminescent assay. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463190, AID463194, AID504542, AID504544] | ChEMBL. | No reference |
Potency (functional) | 0.0032 uM | PubChem BioAssay. qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 1 um | PUBCHEM_BIOASSAY: VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 1.2589 um | PUBCHEM_BIOASSAY: qHTS for inhibitors of ROR gamma transcriptional activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 18.526 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 32.6427 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | 32.6427 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS Assay for Modulators of Lamin A Splicing. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 56.2341 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.